Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis
Vergleich gastrointestinale Nebenwirkungen von GLP-1-Rezeptoragonisten und Multi-Target-Analoga bei Typ-2-Diabetes: Bayes'sche Netzwerkmetaanalyse
Frontiers in Pharmacology · 19.09.2025 · 16
DOI: 10.3389/fphar.2025.1613610 ↗Auf einen Blick
48 RCTs mit 27.729 Teilnehmenden verglichen gastrointestinale Nebenwirkungen verschiedener GLP-1RAs und Multi-Target-Analoga bei Typ-2-Diabetes. Die Risiken unterschieden sich je nach Wirkstoff.
Fragestellung
Wie unterscheiden sich gastrointestinale Nebenwirkungen verschiedener GLP-1RAs und Multi-Target-Analoga bei Erwachsenen mit Typ-2-Diabetes?
Methode
Systematische Suche in PubMed, Embase, Cochrane Library und ClinicalTrials.gov nach RCTs; Bayes'sche Netzwerkmetaanalyse von OR und 95 %-KI.
Ergebnisse
48 RCTs mit 27.729 Teilnehmenden. Gesamtrate gastrointestinaler Nebenwirkungen 11,66 %; Übelkeit 21,49 %, verminderter Appetit 5,49 %. Tirzepatid: höchstes Risiko für Übelkeit und Diarrhö; Dulaglutid und Lixisenatid: niedrigste Risiken.
Schlussfolgerung der Autor:innen
Die Studie zeigt deutliche Unterschiede im Profil gastrointestinaler Nebenwirkungen verschiedener GLP-1RAs. Tirzepatid wies das höchste Risiko auf, Dulaglutid und Exenatid eine relativ bessere Verträglichkeit.
Kernaussagen
- 48 RCTs mit 27.729 Teilnehmenden
- Gastrointestinale Nebenwirkungen insgesamt 11,66 %
- Risiko je nach Wirkstoff unterschiedlich; Tirzepatid am höchsten
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.09.2025. Verfasst von Xingmiao Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangzhou Panyu District Eighth People's Hospital, Guangzhou, China. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
This study aims to evaluate and compare the gastrointestinal adverse effects associated with different GLP-1 receptor agonists (GLP-1RAs) and multi-target analogs in patients with type 2 diabetes mellitus (T2DM) using a Bayesian network meta-analysis.
Methods
A systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was conducted to identify randomized controlled trials (RCTs) assessing the gastrointestinal adverse events of GLP-1RAs in T2DM patients. Inclusion criteria included adult patients with confirmed T2DM receiving any GLP-1RA, with the outcomes focused on gastrointestinal adverse events such as nausea, vomiting, diarrhea, constipation, dyspepsia, and reduced appetite. Bayesian network meta-analysis was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for the comparison of gastrointestinal side effects among different GLP-1RAs.
Results
A total of 48 RCTs involving 27,729 participants were included in the analysis. The overall incidence of gastrointestinal adverse events was 11.66%, with nausea being the most frequent (21.49%) and reduced appetite the least frequent (5.49%). Tirzepatide had the highest risk of inducing nausea and diarrhea, while dulaglutide and lixisenatide had the lowest risks. Exenatide exhibited the highest incidence of vomiting, while dulaglutide showed a lower risk. Semaglutide demonstrated a significantly higher risk of diarrhea compared to other GLP-1RAs.
Conclusion
This study highlights significant differences in the gastrointestinal adverse event profiles of various GLP-1RAs. Tirzepatide exhibited the highest risk of gastrointestinal side effects, whereas dulaglutide and exenatide showed relatively better tolerability. These findings provide valuable insights for clinicians to make informed treatment decisions, emphasizing the importance of individualized therapy based on patient tolerance. Systematic Review Registration CRD42024592308.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Guangzhou Panyu District Eighth People's Hospital, Guangzhou, China.
- Department of Pharmacy, Guangdong Second Provincial General Hospital, Guangzhou, China.
- Department of Internal Medicine, Guangzhou Panyu District Eighth People's Hospital, Guangzhou, China.
- Medical College, Shantou University, Shantou, Guangdong, China.
- Department of Pharmacy, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Zitieren
APA
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025). Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1613610
Vancouver
Xie X, Yang S, Deng S, Liu Y, Xu Z, He B. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1613610
BibTeX
@article{Xie2025,
author = {Xie, Xingmiao and Yang, Shuiyuan and Deng, Shuzhen and Liu, Yuying and Xu, Zhibin and He, Binghong},
title = {Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1613610}
}
EUVIMED